Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

PGEN

Precigen Inc

Feb 13 • 04:00PM ET

4.93

+0.19 4.01 %

Healthcare • Biotechnology • USA • NASD

Peers: AMGN BIIB VRTX REGN GILD ILMN INCY SRPT BLUE ARWR

| Held by: XBI IWM VTI VXF IWO IBB SCHA VTWO KOMP IWC

Index	RUT	P/E	-	EPS (ttm)	-1.40	Insider Own	57.09%	Shs Outstand	353.81M	Perf Week	14.92%
Market Cap	1.74B	Forward P/E	-	EPS next Y	-0.18	Insider Trans	-5.62%	Shs Float	151.81M	Perf Month	11.79%
Enterprise Value	1.72B	PEG	-	EPS next Q	-0.08	Inst Own	38.05%	Short Float	27.65%	Perf Quarter	22.64%
Income	-425.87M	P/S	276.44	EPS this Y	-86.70%	Inst Trans	12.48%	Short Ratio	9.49	Perf Half Y	166.49%
Sales	6.31M	P/B	41.66	EPS next Y	79.45%	ROA	-193.82%	Short Interest	41.98M	Perf YTD	17.94%
Book/sh	0.12	P/C	14.40	EPS next 5Y	-	ROE	-507.72%	52W High	5.22 -5.65%	Perf Year	148.99%
Cash/sh	0.34	P/FCF	-	EPS past 3/5Y	-0.39% 25.76%	ROIC	-306.52%	52W Low	1.11 344.14%	Perf 3Y	210.06%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-34.96% -46.64%	Gross Margin	10.14%	Volatility	8.32% 8.75%	Perf 5Y	-40.82%
Dividend TTM	-	EV/Sales	272.81	EPS Y/Y TTM	-155.65%	Oper. Margin	-1706.63%	ATR (14)	0.37	Perf 10Y	-83.22%
Dividend Ex-Date	-	Quick Ratio	3.95	Sales Y/Y TTM	59.20%	Profit Margin	-6750.13%	RSI (14)	58.69	Recom	1.67
Dividend Gr. 3/5Y	- -	Current Ratio	4.04	EPS Q/Q	-1118.87%	SMA20	6.78%	Beta	1.06	Target Price	8.50
Payout	-	Debt/Eq	2.35	Sales Q/Q	206.61%	SMA50	14.63%	Rel Volume	0.54	Prev Close	4.74
Employees	143	LT Debt/Eq	2.32	Earnings	Nov 13 AMC	SMA200	57.94%	Avg Volume	4.42M	Price	4.93
IPO	Aug 08, 2013	Option/Short	Yes / Yes	EPS/Sales Surpr.	-1028.86% 484.40%	Trades		Volume	2,404,572	Change	4.01%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-15-25	Upgrade	JP Morgan	Underweight → Neutral
Mar-22-24	Downgrade	JP Morgan	Neutral → Underweight
May-23-23	Initiated	JP Morgan	Neutral
Nov-18-22	Initiated	Cantor Fitzgerald	Overweight	$7
Feb-25-21	Initiated	Stifel	Buy	$13
Feb-22-21	Initiated	Wells Fargo	Overweight	$14
Feb-18-21	Initiated	B. Riley Securities	Buy	$10
May-08-20	Initiated	H.C. Wainwright	Buy	$5

Feb-13-26 07:14AM	Precigen, Inc. (PGEN) Builds Commercial Stage With Global Regulatory Support (Insider Monkey)
Jan-20-26 08:05AM	New Expert Consensus Published in The Laryngoscope Recommends PAPZIMEOS (zopapogene imadenovec) as the New Standard of Care First-Line Treatment for Adults with Recurrent Respiratory Papillomatosis (PR Newswire)
Jan-12-26 08:00AM	Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-and-Only FDA-Approved Therapy for RRP at the 44th Annual J.P. Morgan Healthcare Conference (PR Newswire) -9.91%
Jan-05-26 04:05PM	Precigen to Present at the 44th Annual J.P. Morgan Healthcare Conference (PR Newswire) +8.85%
Nov-14-25 12:01AM	Precigen Inc (PGEN) Q3 2025 Earnings Call Highlights: FDA Approval and U.S. ... (GuruFocus.com) +25.65%
04:05PM	Loading…
Nov-13-25 04:05PM	Precigen Reports Third Quarter 2025 Financial Results and Business Updates (PR Newswire)
Nov-06-25 04:30PM	Precigen to Announce Third Quarter 2025 Financial Results and Provide Business Updates on November 13 (PR Newswire)
Oct-26-25 06:05AM	Precigen Reports Positive Long-Term Follow-Up Data for FDA-Approved RRP Therapy, PAPZIMEOS (Insider Monkey)
Oct-13-25 07:00AM	Precigen Announces Long-Term Follow-Up Results Highlighting Ongoing Durable Complete Responses after Treatment with PAPZIMEOS, the First and Only FDA-approved Therapy for Adults with Recurrent Respiratory Papillomatosis (PR Newswire)
Sep-23-25 07:23PM	Precigen, Inc. (PGEN) Secures $125M to Accelerate PAPZIMEOS Commercialization (Insider Monkey)
Sep-20-25 02:43AM	Precigen, Inc. (PGEN) Bolsters Financial Standing to Enhance PAPZIMEOS Commercialization (Insider Monkey)
Sep-15-25 08:17AM	Precigen Signs a Credit Facility Agreement Worth $125 Million to Support PAPZIMEOS (Insider Monkey) -5.28%
Sep-12-25 03:41AM	4 years from clinic to approval Precigens unprecedented FDA nod and what comes next (Pharma Voice) -8.45%
Sep-11-25 03:31AM	Precigen's (PGEN) Papzimeos Push Sparks Multibagger Ascent, Boosted by Analyst Optimism (Insider Monkey)
Sep-07-25 08:23AM	These 2 Healthcare Stocks More Than Doubled Recently and Could Soar Higher, According to Wall Street Analysts (Motley Fool)
07:00AM	Loading…
Sep-03-25 07:00AM	Precigen Announces Up to $125 Million Non-Dilutive Financing (PR Newswire)
Sep-02-25 12:57AM	Cantor Fitzgerald Reaffirms Overweight Rating on Precigen (PGEN) (Insider Monkey) +5.54%
Aug-28-25 10:00AM	INO Stock Soars as FDA Backs Rolling BLA for Rare Lung Disease Drug (Zacks)
Aug-26-25 08:39AM	Citizens JMP Raises PT on Precigen from $6 to $8, Keeps Outperform Rating (Insider Monkey) +7.04%
Aug-25-25 11:56PM	H.C. Wainwright Remains Bullish on Precigen (PGEN) (Insider Monkey)
11:04AM	PGEN Stock Surges 144% in August on FDA Nod for Rare Lung Disease Drug (Zacks)
10:30AM	BC-Most Active Stocks (Associated Press Finance)
08:05AM	Precigen to Participate in Upcoming Virtual Fireside Chats Hosted by Cantor and H.C. Wainwright (PR Newswire)
Aug-20-25 12:22AM	Precigen (PGEN) Secures FDA Approval for Papillomatosis Treatment (Insider Monkey)
Aug-18-25 10:30AM	BC-Most Active Stocks (Associated Press Finance)
07:42AM	FDA approves Papzimeos as first therapy for HPV-caused airway disease (Pharmaceutical Technology)
Aug-15-25 10:45AM	Hope Realized: FDA Approves Papzimeos for Adults with Recurrent Respiratory Papillomatosis (RRP) (Business Wire) +58.92%
10:30AM	BC-Most Active Stocks (Associated Press Finance)
07:20AM	Precigen wins immunotherapy approval; Pfizer sickle cell drug fails trial (BioPharma Dive)
07:00AM	Precigen Announces Full FDA Approval of PAPZIMEOS (zopapogene imadenovec-drba), the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory Papillomatosis (PR Newswire)
04:05PM	Loading…
May-14-25 04:05PM	Precigen Reports First Quarter 2025 Financial Results and Business Updates (PR Newswire) -5.19%
Apr-22-25 12:00PM	Patient Capital Management Q1 2025 Investment Review (Seeking Alpha) +11.68%
Apr-16-25 08:05AM	Precigen and Recurrent Respiratory Papillomatosis Foundation to Host the 2025 International RRP Awareness Day on June 11th (PR Newswire)
Mar-27-25 10:19AM	Is Precigen (PGEN) The Hot Biotech Stock Under $5? (InsiderMonkey)
Mar-21-25 06:23PM	Precigen Inc (PGEN) Q4 2024 Earnings Report Preview: What To Expect (GuruFocus.com)
Mar-19-25 07:47PM	Precigen, Inc. (PGEN) Q4 2024 Earnings Call Transcript (SeekingAlpha) +7.19%
06:25PM	Precigen, Inc. (PGEN) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Precigen Reports Full Year 2024 Financial Results and Business Updates (PR Newswire)
Mar-13-25 08:05AM	Precigen to Announce Full Year 2024 Financial Results and Provide Business Updates on March 19th (PR Newswire)
Mar-01-25 05:27PM	Why Precigen, Inc. (PGEN) is Skyrocketing So Far in 2025 (Insider Monkey)
Feb-25-25 08:05AM	FDA Grants Priority Review to Precigen's BLA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis with PDUFA Target Action Date Set for August 27, 2025 (PR Newswire)
Jan-13-25 07:00AM	Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire) -8.94%
Jan-09-25 08:30AM	Precigen to Present at the 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-30-24 07:00AM	Precigen Completes Submission of BLA with Request for Priority Review to the FDA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (PR Newswire) +28.47%
Dec-27-24 09:00AM	Precigen Announces $79.0 Million Private Placement Offering of Convertible Preferred Stock (PR Newswire)
Nov-14-24 04:30PM	Precigen Reports Third Quarter 2024 Financial Results and Business Updates (PR Newswire) -7.11%
Nov-12-24 04:05PM	Precigen to Participate in the Stifel 2024 Healthcare Conference (PR Newswire) -5.04%
Sep-16-24 04:30PM	Precigen to Participate in the 2024 Cantor Global Healthcare Conference (PR Newswire)
Aug-14-24 04:05PM	Precigen Reports Second Quarter and First Half 2024 Financial Results and Business Updates (PR Newswire)
01:54PM	Hedge Fund and Insider Trading News: Nelson Peltz, Jana Partners, Whitebox Advisors, Caxton Associates LP, Altium Capital, Soros Fund Management, Elliott Investment Management, Balyasny Asset Management, Precigen Inc (PGEN), Vulcan Materials Company (VMC), and More (Insider Monkey)
Aug-09-24 08:00AM	Precigen to Announce Second Quarter and First Half 2024 Financial Results on August 14th (PR Newswire) -13.39%
Aug-07-24 09:30PM	Precigen Announces Pricing of $30.0 Million Public Offering of Common Stock (PR Newswire) -12.59% +7.63%
Aug-06-24 04:04PM	Precigen Announces Proposed $30 Million Public Offering of Common Stock (PR Newswire)
04:01PM	Precigen Strategically Prioritizes Portfolio to Focus on First Potential Gene Therapy Launch (PR Newswire)
Jul-23-24 08:01AM	Precigen Appoints Phil Tennant as Chief Commercial Officer to Spearhead First Potential Gene Therapy Launch (PR Newswire)
Jun-03-24 09:30AM	Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response (PR Newswire) +11.43%
May-23-24 05:00PM	Precigen to Host a Webcast on June 3rd to Detail Pivotal Study Results of PRGN-2012 in Recurrent Respiratory Papillomatosis Presented at the 2024 ASCO Annual Meeting (PR Newswire)
May-14-24 05:20PM	Precigen, Inc. (PGEN) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +5.11%
04:05PM	Precigen Reports First Quarter 2024 Financial Results and Business Updates (PR Newswire)
08:21AM	Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-08-24 04:05PM	Precigen to Announce First Quarter 2024 Financial Results on May 14th and Host a Conference Call on June 3rd following the Late-breaking Oral Presentation for PRGN-2012 at the 2024 ASCO Annual Meeting (PR Newswire)
Apr-24-24 10:20AM	Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting (PR Newswire)
09:00AM	Actym Therapeutics Appoints Thomas Smart as CEO (PR Newswire)
Mar-28-24 04:05PM	Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th (PR Newswire)
Mar-27-24 08:20AM	Analysts on Wall Street Lower Ratings for These 10 Stocks (Insider Monkey)
Mar-20-24 10:07AM	Precigen, Inc. (NASDAQ:PGEN) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-19-24 08:53PM	PGEN Stock Earnings: Precigen Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace)
05:31PM	Precigen Inc (PGEN) Reports Full Year 2023 Financial Results (GuruFocus.com)
04:05PM	Precigen Reports Full Year 2023 Financial Results and Business Updates (PR Newswire)
Mar-12-24 04:05PM	Precigen to Participate in a Fireside Chat Hosted by Cantor Fitzgerald to Discuss PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis (PR Newswire)
Mar-05-24 04:05PM	Precigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19th (PR Newswire)
Feb-06-24 04:05PM	Precigen to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference (PR Newswire)
Jan-16-24 08:05AM	Precigen Receives Orphan Drug Designation for PRGN-2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission (PR Newswire)
Jan-08-24 08:30AM	Precigen Highlights Pipeline Updates to be Presented at the 42nd Annual J.P. Morgan Healthcare Conference (PR Newswire) +8.53%
Jan-02-24 12:40PM	Hedge Fund and Insider Trading News: David Einhorn, Bill Ackman, D. E. Shaw, Steve Cohen, Rob Citrone, Saba Capital, HighPeak Energy, Inc (HPK), Precigen Inc (PGEN), and More (Insider Monkey) +5.22%
Dec-18-23 04:05PM	Precigen to Present at the 42nd Annual J.P. Morgan Healthcare Conference (PR Newswire) -5.74%
Nov-29-23 04:05PM	Precigen to Participate in the JMP Securities Hematology and Oncology Summit (PR Newswire)
Nov-09-23 04:55PM	Precigen Reports Third Quarter 2023 Financial Results and Progress of Clinical Programs (PR Newswire) -13.49%
Nov-07-23 04:05PM	Precigen to Participate in the Stifel 2023 Healthcare Conference (PR Newswire) +12.93%
Sep-19-23 04:05PM	Precigen to Participate in Upcoming Leading Investor and Industry Conferences (PR Newswire) -8.33% +6.06%
Aug-09-23 08:00AM	Precigen Reports Second Quarter and First Half 2023 Financial Results and Provides Update on Portfolio Prioritization and Capital Allocation Strategies to Extend Projected Cash Runway into 2025 (PR Newswire) +6.90%
07:05AM	Precigen Announces FDA Confirmation that the Ongoing Phase 1/2 Study of PRGN-2012 AdenoVerse Immunotherapy Will Serve as the Pivotal Study to Support Accelerated Approval (PR Newswire)
Aug-03-23 04:05PM	Precigen to Announce Second Quarter and First Half 2023 Financial Results on August 9th (PR Newswire) -6.67%
Jun-20-23 07:30AM	Precigen Receives Breakthrough Therapy Designation for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis (PR Newswire)
Jun-05-23 04:05PM	Precigen Announces Positive Phase 1 Data for PRGN-3005 Autologous UltraCAR-T® Cells Manufactured Overnight for Infusion Next Day to Advanced Stage Platinum Resistant Ovarian Cancer Patients (PR Newswire)
Jun-03-23 12:00PM	Precigen Announces Positive Phase 1 Data for Off-the-Shelf PRGN-2009 AdenoVerse Immunotherapy Alone and in Combination with an Investigational Checkpoint Inhibitor in Patients with Recurrent/Metastatic HPV-associated Cancers (PR Newswire)
May-31-23 08:05AM	Precigen Receives FDA Clearance of IND to Initiate Phase 2 Study of PRGN-2009 Off-the-Shelf AdenoVerse Immunotherapy in Combination with Pembrolizumab to Treat Patients with Recurrent or Metastatic Cervical Cancer (PR Newswire)
May-10-23 08:00AM	Precigen Reports First Quarter 2023 Financial Results and Business Updates (PR Newswire)
May-03-23 08:30AM	Precigen to Announce First Quarter 2023 Financial Results on May 10th (PR Newswire) +8.85%
Apr-26-23 04:05PM	Precigen to Present Latest Clinical Advancements for PRGN-3005 UltraCAR-T® and PRGN-2009 Off-the-Shelf AdenoVerse Immunotherapy at the 2023 ASCO Annual Meeting (PR Newswire)
Apr-17-23 09:01AM	Precigen Presents Preclinical Data for the Next Generation Mesothelin UltraCAR-T® with Intrinsic PD-1 Blockade at the AACR Annual Meeting 2023 (PR Newswire) +10.48%
Apr-03-23 04:30PM	Precigen Regains Exclusive Rights to Proven CAR-T Targets, CD19 and BCMA, to Enable Unencumbered Development and Commercialization of UltraCAR-T® (PR Newswire) +5.66% -8.04%
Mar-29-23 08:05AM	Precigen Announces Further Advancement of UltraCAR-T® Platform with First Patient Dosed in Phase 1/1b Dose Escalation/Dose Expansion Study of PRGN-3007 in Advanced ROR1+ Hematological and Solid Tumors (PR Newswire) +15.44%
Mar-28-23 08:05AM	Precigen to Participate in a Virtual Fireside Chat at Cantor's "The Future of Oncology" Virtual Symposium (PR Newswire)
Mar-06-23 04:05PM	Precigen Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates (PR Newswire) +17.39%
Feb-07-23 08:00AM	Precigen Is Pioneering a Nonsurgical Treatment for a Debilitating Respiratory Disease; Positive Data Released on Recurrent Respiratory Papillomatosis Showed a 50% Complete Response (News Direct)
Jan-30-23 02:34PM	Germantown's Precigen raises $75M to advance treatments for rare diseases (American City Business Journals)
Jan-27-23 04:05PM	Precigen Announces Closing of Public Offering of Common Stock (PR Newswire)
Jan-24-23 10:40PM	Precigen Announces Pricing of $75.0 Million Public Offering of Common Stock (PR Newswire) -24.66%
04:05PM	Precigen Announces Proposed $75.0 Million Public Offering of Common Stock (PR Newswire)

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the following segments: Biopharmaceuticals, Exemplar, and Trans Ova. The Biopharmaceuticals segment is involved in advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases. It also engages in pioneering a proprietary class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics. The Exemplar segment is focused on developing research models and services for healthcare research applications. The Trans Ova segment provides bovine reproductive technologies. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
KIRK RANDAL J	Director	Dec 22 '25	Sale	4.18	1,900,036	7,942,150	341,189	Dec 22 08:48 PM
Randal J. Kirk	Director	Dec 22 '25	Proposed Sale	4.32	1,900,036	8,208,156		Dec 22 08:19 PM
KINDLER JEFFREY B	Director	Dec 12 '25	Sale	3.63	235,467	855,899	110,603	Dec 16 04:16 PM
Jeffrey Kindler	Director	Dec 12 '25	Proposed Sale	3.69	235,467	868,873		Dec 12 06:27 PM
KIRK RANDAL J	Director	Nov 19 '25	Sale	4.47	1,086,153	4,855,104	7,434,384	Nov 21 07:54 PM
KIRK RANDAL J	Director	Nov 20 '25	Sale	4.08	942,832	3,846,755	6,491,552	Nov 21 07:54 PM
KIRK RANDAL J	Director	Nov 21 '25	Sale	3.83	937,308	3,589,890	5,554,244	Nov 21 07:54 PM
KIRK RANDAL J	Director	Nov 20 '25	Proposed Sale	4.08	942,832	3,843,885		Nov 20 05:33 PM
KIRK RANDAL J	Director	Nov 19 '25	Proposed Sale	4.22	1,086,153	4,583,565		Nov 19 05:23 PM
KINDLER JEFFREY B	Director	Sep 30 '25	Sale	3.38	106,837	361,109	346,070	Oct 01 05:16 PM
KINDLER JEFFREY B	Director	Sep 29 '25	Sale	3.60	67,523	243,083	452,907	Oct 01 05:16 PM
KIRK RANDAL J	Director	Sep 30 '25	Sale	3.41	1,809,667	6,170,964	14,597,161	Sep 30 05:44 PM
KIRK RANDAL J	Director	Sep 30 '25	Proposed Sale	3.63	1,809,667	6,569,091		Sep 30 05:26 PM
Jeffrey Kindler	Director	Sep 30 '25	Proposed Sale	3.29	106,837	351,494		Sep 30 04:21 PM
Shah Rutul R	Chief Operating Officer	Sep 26 '25	Buy	3.40	2,000	6,800	405,959	Sep 30 04:07 PM
Tennant Phil	Chief Commercial Officer	Sep 29 '25	Buy	3.58	6,000	21,480	65,031	Sep 30 04:04 PM
Jeffrey Kindler	Director	Sep 29 '25	Proposed Sale	3.63	67,523	245,108		Sep 29 04:12 PM
Thomasian Harry Jr.	Chief Financial Officer	Sep 25 '25	Buy	3.62	8,284	29,988	465,694	Sep 26 05:01 PM
Thomasian Harry Jr.	Chief Financial Officer	Sep 26 '25	Buy	3.42	2,932	10,027	468,626	Sep 26 05:01 PM
KIRK RANDAL J	Director	Sep 19 '25	Sale	3.68	3,596,892	13,236,563	8,520,537	Sep 19 08:46 PM
KIRK RANDAL J	Director	Sep 18 '25	Sale	3.86	1,403,360	5,416,970	12,117,429	Sep 19 08:46 PM
KIRK RANDAL J	Director	Sep 19 '25	Proposed Sale	3.85	252	970		Sep 19 04:47 PM
KIRK RANDAL J	Director	Sep 18 '25	Proposed Sale	3.92	5,000,000	19,625,000		Sep 18 01:30 PM
AGEE NANCY H	Director	Sep 04 '25	Buy	4.60	15,000	69,000	217,841	Sep 05 05:46 PM
AGEE NANCY H	Director	Aug 28 '25	Buy	4.65	10,645	49,491	202,841	Aug 29 04:21 PM
AGEE NANCY H	Director	Aug 19 '25	Buy	3.20	15,360	49,152	192,196	Aug 29 04:21 PM
KIRK RANDAL J	Director	Mar 14 '25	Option Exercise	0.00	174,825	0	64,779,510	Mar 17 06:38 PM

Open in Screener

PRAX

Praxis Precision Medicines Inc

Feb 13 • 04:00PM ET

317.25

-15.67 -4.71 %

Healthcare • Biotechnology • USA • NASD

PRAX Praxis Precision Medicines Inc daily Stock Chart

Peers: SAGE ITCI ACAD NBIX BHVN AXSM VNDA RLMD HELP DFTX

| Held by: VTI IWM XBI VXF IWN IBB SCHA VTWO IWC VHT

Index	RUT	P/E	-	EPS (ttm)	-12.90	Insider Own	7.77%	Shs Outstand	27.41M	Perf Week	-0.73%
Market Cap	8.69B	Forward P/E	-	EPS next Y	-12.63	Insider Trans	-1.79%	Shs Float	25.28M	Perf Month	6.30%
Enterprise Value	8.43B	PEG	-	EPS next Q	-3.10	Inst Own	82.28%	Short Float	15.27%	Perf Quarter	72.78%
Income	-273.04M	P/S	1165.54	EPS this Y	-28.09%	Inst Trans	-4.66%	Short Ratio	5.09	Perf Half Y	565.09%
Sales	7.46M	P/B	19.55	EPS next Y	3.43%	ROA	-67.20%	Short Interest	3.86M	Perf YTD	7.64%
Book/sh	16.23	P/C	32.55	EPS next 5Y	16.47%	ROE	-75.20%	52W High	335.75 -5.51%	Perf Year	266.09%
Cash/sh	9.75	P/FCF	-	EPS past 3/5Y	44.28% 8.54%	ROIC	-79.49%	52W Low	26.70 1088.20%	Perf 3Y	473.17%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	97.87%	Volatility	5.68% 5.97%	Perf 5Y	-59.74%
Dividend TTM	-	EV/Sales	1129.78	EPS Y/Y TTM	-25.33%	Oper. Margin	-3927.51%	ATR (14)	18.07	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	5.18	Sales Y/Y TTM	364.98%	Profit Margin	-3658.53%	RSI (14)	56.05	Recom	1.44
Dividend Gr. 3/5Y	- -	Current Ratio	5.18	EPS Q/Q	-22.38%	SMA20	1.06%	Beta	2.88	Target Price	572.88
Payout	-	Debt/Eq	0.00	Sales Q/Q	-100.00%	SMA50	9.78%	Rel Volume	0.44	Prev Close	332.92
Employees	116	LT Debt/Eq	0.00	Earnings	Feb 19 BMO	SMA200	145.35%	Avg Volume	758.09K	Price	317.25
IPO	Oct 16, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	3.06% -100.00%	Trades		Volume	332,268	Change	-4.71%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-02-26	Initiated	Wells Fargo	Equal Weight	$282
Dec-15-25	Reiterated	Oppenheimer	Outperform	$250 → $750
Nov-19-25	Initiated	BTIG Research	Buy	$424
Jun-02-25	Resumed	Oppenheimer	Outperform	$97
May-07-25	Initiated	Chardan Capital Markets	Buy	$80
Mar-03-25	Reiterated	H.C. Wainwright	Buy	$120 → $105
Feb-11-25	Initiated	Deutsche Bank	Buy	$111
Aug-05-24	Initiated	Oppenheimer	Outperform	$134
Jun-24-24	Initiated	Needham	Buy	$145
Jun-18-24	Initiated	Guggenheim	Buy	$155
May-01-24	Initiated	Robert W. Baird	Outperform	$117
Sep-19-23	Initiated	Truist	Buy	$10
Jun-06-22	Downgrade	Wedbush	Outperform → Neutral	$4
Dec-16-21	Initiated	H.C. Wainwright	Buy	$48
Aug-26-21	Initiated	BofA Securities	Buy	$28
Apr-26-21	Initiated	William Blair	Outperform
Nov-11-20	Initiated	Wedbush	Outperform	$40
Nov-10-20	Initiated	Piper Sandler	Overweight	$65
Nov-10-20	Initiated	Evercore ISI	Outperform	$55
Nov-10-20	Initiated	Cowen	Outperform

Show Previous Ratings

Feb-14-26 08:02PM	Praxis Precision Medicines Eyes Mid-February Dual NDA Filings, Maps ET Launch and Epilepsy Pipeline (MarketBeat)
Feb-13-26 09:53AM	Guggenheim Raises Target on Praxis Precision Medicines (PRAX) to $800 (Insider Monkey)
Feb-09-26 04:01PM	Praxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-04-26 04:01PM	Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-03-26 06:40AM	SEQSTER and Praxis expand collaboration to expedite CNS disorder trials (Clinical Trials Arena)
09:47AM	Loading…
Feb-02-26 09:47AM	Palantir upgraded, Best Buy downgraded: Wall Street's top analyst calls (The Fly)
Jan-15-26 11:35AM	Praxis Precision Medicines, Inc. (PRAX) a Strong Buy, Per Wall Street Consensus (Insider Monkey)
Jan-13-26 04:30PM	Praxis Precision Medicines Appoints Global Epilepsy Leader Dr. Orrin Devinsky as Head of Clinical Strategy (GlobeNewswire) +6.28%
Jan-12-26 08:00AM	Praxis Precision Medicines Enters Its Next Chapter Following a Pivotal Year of Progress (GlobeNewswire)
Jan-11-26 01:07AM	Needham Analyst Keeps a Buy Rating on Praxis Precision Medicines, Inc. (PRAX) (Insider Monkey)
Jan-09-26 04:01PM	Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-08-26 04:45PM	Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments (GlobeNewswire)
Jan-06-26 11:15PM	Praxis Precision Medicines, Inc. Announces Pricing of $575 Million Public Offering (GlobeNewswire) +7.23%
04:03PM	Praxis Precision Medicines, Inc. Announces Proposed Public Offering (GlobeNewswire)
Dec-30-25 08:05AM	Praxis Precision granted Breakthrough Therapy designation for Ulixacaltamide (TipRanks)
07:39PM	Loading…
Dec-29-25 07:39PM	Why Praxis Precision Medicines Stock Popped Today (Motley Fool) +13.25%
04:32PM	Stocks Settle Lower as Weakness in Big Tech Weighs (Barchart)
10:02AM	Stocks Slip Due to Weakness in Megacap Technology Stocks (Barchart)
08:00AM	Praxis Precision Medicines Announces the FDA Has Granted Breakthrough Therapy Designation for Ulixacaltamide HCl in Essential Tremor (GlobeNewswire)
07:52AM	Here Are Mondays Top Wall Street Analyst Research Calls: Doximity, KB Home, NVIDIA, Okta, On Holdings, Take-Two Interactive, Vail Resorts, and More (24/7 Wall St.)
Dec-12-25 05:18AM	Praxis tees up another approval filing; Geron turns to layoffs (BioPharma Dive)
Dec-11-25 08:00AM	Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026 (GlobeNewswire)
07:44AM	TD Cowen Lifts Praxis Precision Medicines Inc. (PRAX) Price Target amid NDA for Essential Tremor Treatment (Insider Monkey)
Dec-09-25 04:01PM	Praxis Precision Medicines Announces Alignment with FDA on Simplified and Accelerated Registrational Pathway for Elsunersen in Early Onset SCN2A Developmental and Epileptic Encephalopathy (GlobeNewswire)
12:20AM	Praxis Precision Medicines Inc. (PRAX) Secures Analyst Confidence After Key FDA and Trial Wins (Insider Monkey)
Dec-08-25 10:39AM	PRAX Stock Skyrockets 520% in 3 Months: Here's What You Need to Know (Zacks) +9.27%
08:00AM	Praxis AES Wrap-up: Best-in-Class Potential Across Rare Pediatric and Adult Epilepsies (GlobeNewswire)
Dec-05-25 04:58PM	Health Care Roundup: Market Talk (The Wall Street Journal) +30.54%
04:15PM	Praxis Surges 31%, Hitting Another 3-Year High, On A Surprise Win In Epilepsy (Investor's Business Daily)
12:34PM	Stock Market Today: S&P 500 and Nasdaq Gain For Fourth Straight Day Ahead of Highly-Anticipated Fed Policy Meeting (TheStreet)
12:34PM	Loading…
12:34PM	Stock Market Today: Nasdaq, Dow Gain As Consumer Sentiment Rises for First Time in Five Months (TheStreet)
05:00AM	Praxis soars higher; Bristol Myers CAR-T therapy wins broader use (BioPharma Dive)
Dec-04-25 04:10PM	Praxis Precision Medicines Announces Positive Results from EMBOLD Study for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies (GlobeNewswire)
04:01PM	Praxis Precision Medicines Announces Positive Pre-NDA Meeting with FDA for Ulixacaltamide in Essential Tremor (GlobeNewswire)
Dec-03-25 04:01PM	Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-24-25 04:01PM	Praxis to present latest preclinical and clinical advancements across leading epilepsy portfolio at the 2025 American Epilepsy Society (AES) Annual Meeting (GlobeNewswire) +12.40%
Nov-20-25 04:01PM	Praxis Precision Medicines to Participate in Upcoming Fireside Chat (GlobeNewswire) -13.33%
Nov-19-25 09:07AM	Here Are Wednesdays Top Wall Street Analyst Research Calls: DoorDash, Freeport-McMoRan, GitLab, Home Depot, Medtronic, Molson-Coors, and More (24/7 Wall St.)
Nov-06-25 08:00AM	Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-05-25 04:01PM	Praxis Precision Medicines to Participate in Upcoming Investor Conferences (GlobeNewswire)
08:00AM	Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Nov-04-25 08:00AM	Praxis announces accelerated development path for relutrigine in SCN2A and SCN8A DEE patients following positive FDA feedback (GlobeNewswire) -5.63%
Nov-03-25 11:15AM	Oppenheimer Lifts Price Target for Praxis Medicines (PRAX), Keeps Outperform Rating (Insider Monkey) -8.44%
Oct-29-25 10:00AM	Praxis Precision Medicines, Inc. (PRAX) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-26-25 03:47AM	Meet the Biotech Stock That Just Jumped 251% Higher (Motley Fool)
Oct-22-25 07:41AM	Praxis Precision Medicines Reports Positive Phase 3 Results for Ulixacaltamide in Essential Tremor (Insider Monkey)
Oct-17-25 10:09AM	Praxis Precision (PRAX) Triples on Stellar Drug Trial Results (Insider Monkey) +16.77%
09:10AM	Praxis Precision Medicines (PRAX) Surges 183.7%: Is This an Indication of Further Gains? (Zacks)
08:49AM	Tesla, Nvidia, Rigetti, Praxis: Trending Stocks (Yahoo Finance Video)
Oct-16-25 11:45PM	Praxis Precision Medicines, Inc. Announces Pricing of $525 Million Public Offering (GlobeNewswire) +183.71%
04:01PM	Praxis Precision Medicines, Inc. Announces Proposed Public Offering (GlobeNewswire)
03:49PM	Praxis Precision surges, analysts see blockbuster potential for ulixacaltamide (Investing.com)
02:14PM	Praxis Precision's tremor-drug trial has succeeded where others have failed. The stock is skyrocketing. (MarketWatch)
12:07PM	A Treatment for Tremors Is Back From the Dead. This Stock Is Up 200%. (Barrons.com)
11:53AM	The 'Groundbreaking' Results That Sent Praxis Precision Medicines Up 200% (Investor's Business Daily)
11:35AM	This Strong Buy Stock Has More Than Tripled Today. Should You Buy It Here? (Barchart)
08:21AM	A longshot bet on a tremor drug pays off (BioPharma Dive)
07:00AM	Praxis Precision Medicines Announces Positive Topline Results from Two Pivotal Phase 3 Studies of Ulixacaltamide HCl in the Essential3 Program for Essential Tremor (GlobeNewswire)
Oct-02-25 04:01PM	Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-29-25 07:00AM	ReCode Therapeutics Announces Over $29 Million in Additional Financing to Advance Genetic Medicines Pipeline and Provides Corporate Update (Business Wire)
Sep-04-25 04:01PM	Praxis Precision Medicines to Participate in September Investor Conferences (GlobeNewswire)
Sep-03-25 04:01PM	Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-29-25 08:00AM	Praxis Precision Medicines to Participate in Upcoming Fireside Chat (GlobeNewswire)
Aug-25-25 04:01PM	Praxis Medicines to Present at 36th International Epilepsy Congress 2025 in Lisbon, Showcasing Latest RADIANT Study Data and Leading Precision Epilepsy Pipeline (GlobeNewswire)
Aug-06-25 04:01PM	Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-05-25 06:09PM	Praxis Precision Medicines to Participate in Upcoming Fireside Chat (GlobeNewswire) -6.46%
07:38AM	Praxis vormatrigine eliminates seizures in 22% of patients in Phase II trial (Clinical Trials Arena)
03:01AM	Praxis Precision Medicines Inc (PRAX) Q2 2025 Earnings Call Highlights: Vormatrigine Shows ... (GuruFocus.com)
Aug-04-25 08:24PM	Praxis Precision Medicines to Participate in Upcoming Fireside Chat (GlobeNewswire) -5.55%
01:38PM	Praxis' Epilepsy Treatment Shows Promise With Decreased Seizures (Benzinga)
08:30AM	Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2025 Financial Results (GlobeNewswire)
08:23AM	A brain biotech slumps even with best case seizure data (BioPharma Dive)
08:00AM	Praxis Precision Medicines Announces Positive, Best-in-Disease Topline Results in Patients with Focal Onset Seizures from the RADIANT Study of Vormatrigine (GlobeNewswire)
Jul-29-25 08:00AM	Praxis Precision Medicines to Host Conference Call to Announce Topline Results from the RADIANT Trial and Provide Second Quarter 2025 Financial Results (GlobeNewswire)
Jul-17-25 08:00AM	Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Relutrigine for the Treatment of Seizures Associated with SCN2A and SCN8A Developmental and Epileptic Encephalopathies (GlobeNewswire)
Jul-10-25 08:00AM	Acadia Emerges From Behind The Scenes With A Potential $12 Billion Opportunity (Investor's Business Daily)
Jul-02-25 05:00PM	Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.30%
Jun-24-25 05:42PM	Truist Financial Remains Bullish on Praxis Precision Medicines (PRAX) (Insider Monkey) +5.60%
Jun-04-25 05:00PM	Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-20-25 08:00AM	Praxis Precision Medicines to Participate in Upcoming Conferences (GlobeNewswire) +6.29%
May-05-25 08:00AM	Praxis Precision Medicines Highlights DEE Clinical Program Updates at Virtual Investor Event (GlobeNewswire)
May-02-25 05:00PM	Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.73%
08:30AM	Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2025 Financial Results (GlobeNewswire)
Apr-08-25 08:00AM	Praxis Precision Medicines to Hold Virtual Investor Event to Discuss Clinical Programs in Developmental and Epileptic Encephalopathies (GlobeNewswire) -9.29%
Apr-03-25 05:00PM	Praxis Precision Medicines to Participate in Upcoming April Conferences (GlobeNewswire) -10.27%
04:00PM	Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-24-25 08:00AM	Praxis Precision Medicines to Present on Late-Stage Programs across Epilepsy and Movement Disorders at the American Academy of Neurology 2025 Annual Meeting (GlobeNewswire)
Mar-04-25 05:00PM	Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.93%
08:05AM	Praxis Precision price target lowered to $85 from $150 at Needham (TipRanks)
08:00AM	Praxis Precision Medicines to Participate in Five Upcoming Investor Conferences (GlobeNewswire)
Feb-28-25 09:10AM	Praxis Precision Medicines, Inc. (PRAX) Reports Q4 Loss, Tops Revenue Estimates (Zacks) -40.64%
08:00AM	Praxis Precision Medicines Provides Update on Essential3 and Corporate Update (GlobeNewswire)
06:40AM	Praxis hits trial setback; Bristol Myers lays off staff in New Jersey (BioPharma Dive)
Feb-25-25 10:00AM	Praxis Precision Medicines, Inc. (PRAX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release (Zacks)
Feb-04-25 05:00PM	Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.68%
Feb-03-25 05:00PM	Praxis Precision Medicines to Present at Two February Investor Conferences (GlobeNewswire)
Jan-12-25 09:00PM	Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities (GlobeNewswire)
Jan-06-25 08:00AM	Praxis Precision Medicines to Present at J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-18-24 08:00AM	Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome (GlobeNewswire)
Dec-05-24 08:30AM	GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners (Business Wire) -8.18%

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company, which engages in the genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance. It focuses on two proprietary platforms: Cerebrum and Solidus. The Cerebrum platform utilizes a deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies. The Solidus platform consists of antisense oligonucleotide, or ASO. The company was founded by Kiran Reddy, David Goldstein, and Steven Petrou on September 22, 2015 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Nemiroff Alex	General Counsel and Secretary	Nov 20 '25	Option Exercise	73.76	25,130	1,853,531	45,962	Nov 21 09:41 PM
Nemiroff Alex	General Counsel and Secretary	Nov 20 '25	Sale	193.09	25,130	4,852,256	20,832	Nov 21 09:41 PM
Mastrocola Lauren	Principal Accounting Officer	Nov 20 '25	Option Exercise	61.12	13,600	831,257	24,042	Nov 21 09:39 PM
Mastrocola Lauren	Principal Accounting Officer	Nov 20 '25	Sale	192.08	13,600	2,612,244	10,442	Nov 21 09:39 PM
Nemiroff Alex	Officer	Nov 20 '25	Proposed Sale	193.09	25,130	4,852,249		Nov 20 11:34 AM
Mastrocola Lauren	Officer	Nov 20 '25	Proposed Sale	192.08	13,600	2,612,239		Nov 20 11:25 AM
MITCHELL DEAN J	Director	Sep 24 '25	Option Exercise	39.51	12,251	483,991	17,251	Sep 25 04:40 PM

PGEN

Precigen Inc

PRAX

Praxis Precision Medicines Inc

Upgrade your FINVIZ experience